Key result
Liraglutide protects against Ang II- and pressure overload-induced cardiac damage by reducing oxidative stress and fibrosis.
Answers are grounded in this paper and cite their sources.
Angiotensin II (Ang II), a peptide hormone generated as part of the renin-angiotensin system, has been implicated in the pathophysiology of many cardiovascular diseases such as peripheral artery disease, heart failure, hypertension, coronary artery disease and other conditions. Liraglutide, known as an incretin mimetic, is one of the glucagon-like peptide-1 (GLP-1) receptor agonists, and has been proven to be effective in the treatment of cardiovascular disorders beyond adequate glycemic control. The objective of this review is to compile our recent experimental outcomes-based studies, and provide an overview the cardiovascular protection from liraglutide against Ang II- and pressure overload-mediated deleterious effects on the heart. In particular, the mechanisms of action underlying the inhibition of oxidative stress, vascular endothelial dysfunction, hypertension, cardiac fibrosis, left ventricular hypertrophy and heart failure with liraglutide are addressed. Thus, we support the notion that liraglutide continues to be a useful add-on therapy for the management of cardiovascular diseases.
No takes yet. Share an insight, caveat, or question.
Vandemark et al. (2023) conducted a review in Cardiovascular diseases (Angiotensin II- and pressure overload-mediated deleterious effects on the heart). Liraglutide was evaluated. Liraglutide provides cardiovascular protection against Ang II- and pressure overload-mediated cardiac damage by inhibiting oxidative stress, endothelial dysfunction, fibrosis, and hypertrophy.
Synapse has enriched 10 related papers. Consider them for comparative context: